

# Anti-PD-L1 (Avelumab), Human IgG1 Antibody

rev 01/21

---

**CATALOG NO.:** A2152-100 (100 µg)
 

---

**BACKGROUND DESCRIPTION:** The research-grade biosimilar is a human IgG1 lambda monoclonal antibody that specifically targets programmed death-ligand 1 (PD-L1). Binding of PD-L1 to the PD-1 and B7.1 receptors occurs on T cells and antigen-presenting cells that results in suppression of cytotoxic T-cell activity, T-cell proliferation, and cytokine production. The antibody binds PD-L1 through the FG loops and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This releases the suppression of immune responses and promotes the inhibition of tumor growth. Studies show that the drug is capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. The original drug received FDA approval to treat Merkel cell cancer. It is currently been used in immunotherapy for several cancers.

**ALTERNATE NAMES:** MSB-0010718C, MSB0010682, B7-H, B7H1, B7-H1, CD274, PDCD1L1, PDL1, PD-L1, B7 homolog 1, PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** Lot specific

**HOST/ISOTYPE:** Recombinant / IgG1, lambda

**SOURCE:** CHO cells

**IMMUNOGEN:** Human PD-L1

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

**RELATED PRODUCTS:**

Anti-PD-L1 (Durvalumab), Human IgG1 Antibody (A2109)  
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)  
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)  
 Anti-PD-L1 Humanized Antibody (A1305)  
 Anti-CTLA-4 (Ipilimumab), Humanized Antibody (A2110)

**FOR RESEARCH USE ONLY! Not to be used on humans.**